– Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus pembrolizumab compared to chemotherapy – – Enfortumab vedotin plus pembrolizumab improved median overall survival by more than 15 months vs. chemotherapy – – Results will form the basis of global…